We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+39.03%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.59B
AUM Growth
+$520M
Cap. Flow
+$202M
Cap. Flow %
12.68%
Top 10 Hldgs %
83.78%
Holding
29
New
7
Increased
2
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$181M
2
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$52.8M
3
CCCC icon
C4 Therapeutics
CCCC
+$47.6M
4
SLDB icon
Solid Biosciences
SLDB
+$13.4M
5
APTX
Aptinyx Inc. Common Stock
APTX
+$11.6M

Top Sells

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$48.9M
2
SAGE
Sage Therapeutics
SAGE
+$30.5M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$22M
4
KYMR icon
Kymera Therapeutics
KYMR
+$12.2M
5
PANA.U
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
+$5M

Sector Composition

Rank Sector Weight
1 Healthcare 93.91%
2 Financials 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$528M 33.15%
7,281,307
– –
AVIR icon
2
Atea Pharmaceuticals
AVIR
$402M
$235M 14.73%
+5,615,659
New +$181M
ARQT icon
3
Arcutis Biotherapeutics
ARQT
$3.26B
$112M 7.03%
3,979,292
– –
MRSN
4
DELISTED
Mersana Therapeutics
MRSN
$91.7M 5.76%
137,827
– –
ANNX icon
5
Annexon
ANNX
$883M
$81.1M 5.09%
3,241,628
– –
DRNA
6
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$67.9M 4.26%
3,080,237
-1,000,000
-25% -$22M
SYRS
7
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$62.8M 3.94%
+578,504
New +$52.8M
CCCC icon
8
C4 Therapeutics
CCCC
$400M
$54.4M 3.42%
+1,642,209
New +$47.6M
SLDB icon
9
Solid Biosciences
SLDB
$918M
$53.5M 3.36%
470,690
+212,612
+82% +$13.4M
DVAX
10
DELISTED
Dynavax Technologies
DVAX
$48.5M 3.04%
10,895,773
– –
NRIX icon
11
Nurix Therapeutics
NRIX
$2.69B
$42.2M 2.65%
1,284,314
– –
CNST
12
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$40.3M 2.53%
1,400,000
– –
APTX
13
DELISTED
Aptinyx Inc. Common Stock
APTX
$30.8M 1.93%
8,891,758
+3,333,333
+60% +$11.6M
KYMR icon
14
Kymera Therapeutics
KYMR
$9.03B
$29.7M 1.87%
479,605
-250,001
-34% -$12.2M
SYRE icon
15
Spyre Therapeutics
SYRE
$9.29B
$21.2M 1.33%
108,000
– –
MRNS
16
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$17.5M 1.1%
1,431,058
-1
-0% -$14
CRNX icon
17
Crinetics Pharmaceuticals
CRNX
$8.93B
$15.1M 0.95%
1,071,428
– –
PNT
18
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$13.9M 0.87%
1,000,000
– –
NAUT icon
19
Nautilus Biotechnolgy
NAUT
$110M
$10.8M 0.68%
1,000,000
– –
XFOR icon
20
X4 Pharmaceuticals
XFOR
$421M
$10.6M 0.67%
54,950
– –
SVRA icon
21
Savara
SVRA
$1.17B
$5.9M 0.37%
5,128,593
– –
TNGX icon
22
Tango Therapeutics
TNGX
$4.51B
$5.72M 0.36%
500,000
– –
BLSA
23
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$5.43M 0.34%
+487,500
New +$5.23M
FLACU
24
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$3.11M 0.2%
+300,000
New +$3.13M
JYAC
25
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$3.09M 0.19%
+300,000
New +$3.05M
1
2

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q4 2020 Portfolio in Review

As of Q4 2020, Bain Capital Life Sciences Investors held 29 positions worth $1.59B, up 48% from $1.07B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Bain Capital Life Sciences Investors deployed $202M of net new capital in Q4 2020, opening 7 new positions and adding to 2 existing holdings. Its largest new stake was Atea Pharmaceuticals: 5,615,659 shares worth $235M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 91% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Dicerna Pharmaceuticals, Inc., an estimated $22M trimmed.

  • Bain Capital Life Sciences Investors's largest Q4 2020 buy was Atea Pharmaceuticals: 5,615,659 shares worth $235M.
  • Bain Capital Life Sciences Investors added most to Solid Biosciences in Q4 2020, an estimated $13.4M increase.
  • Bain Capital Life Sciences Investors's biggest Q4 2020 reduction was Dicerna Pharmaceuticals, Inc., cutting an estimated $22M.
  • Bain Capital Life Sciences Investors fully exited Replimune Group in Q4 2020, selling an estimated $48.9M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 84% of its $1.59B portfolio in Q4 2020.
  • Bain Capital Life Sciences Investors opened 7 new positions and closed 3 in Q4 2020.
  • Bain Capital Life Sciences Investors's portfolio value rose 48% quarter-over-quarter to $1.59B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2020, filed 16 Feb 2021.